CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 9 enrolled
Drug / intervention
Beta blockersdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04767061
NCT04767061Phase 4Completed
CompareCT.gov

N-of-1 Trials for Deprescribing Beta-blockers in HFpEF

Weill Medical College of Cornell University·interventional·Posted Feb 23, 2021·Updated Sep 8, 2023

In Brief

A Phase 4 clinical trial evaluating Beta blockers for Heart Failure and 4 related conditions. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to understand the impact of beta-blockers on physical function in older adults with heart failure. We will achieve this objective by conducting N-of-1 trials. N-of-1 trials are personalized experiments that test different treatment options in an individual patient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
CountriesUnited States
CollaboratorsThe New York Community Trust

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedFeb 23, 2021
Enrollment StartApr 1, 2021
Primary CompletionApr 28, 2022
Study CompletionApr 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.4 years ago

Interventions

Beta blockersdrug

The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued. Subjects will be randomized into either ABAB or BABA sequences.